{
    "Question": "Abbott CES 2024 product highlight and specification",
    "Summary": "Abbott\n\nCES 2024 Health Tech Highlights:\n\n- Biowearables for diabetes care and metabolic health, providing real-time insights into glucose levels\n- Connected health tech for personalized data and support, enabling real-time updates for doctors\n- Next-gen diagnostic tests for fast, reliable results, aiding in evaluating brain injuries\n- FreeStyle Libre 3, a continuous glucose monitor delivering real-time readings to smartphones, recognized as a CES 2022 Innovation Awards honoree\n- Lingo continuous glucose monitor tech showcased at CES 2024, offering biosensor for glucose monitoring\n\nAbbott's focus on innovative health technologies aims to empower individuals to take control of their health through advanced biowearables, connected health solutions, and next-generation diagnostic tests. The FreeStyle Libre 3, recognized for its innovation, provides continuous glucose monitoring, while the Lingo continuous glucose monitor tech is poised for expansion into the US market.",
    "Summary_cn": "Abbott\n\nCES 2024健康科技亮点：\n\n- 用于糖尿病和代谢健康的生物可穿戴设备，提供实时血糖水平洞察\n- 用于个性化数据和支持的连接健康技术，能够即时向医生更新信息\n- 下一代诊断测试，快速可靠的结果，有助于评估脑损伤\n- FreeStyle Libre 3，一种持续血糖监测仪，可以实时将读数传输到智能手机上，并获得CES 2022创新奖的认可\n- 在CES 2024上展示的Lingo持续血糖监测技术，提供葡萄糖监测的生物传感器\n\nAbbott专注于创新的健康技术，旨在通过先进的生物可穿戴设备、连接的健康解决方案和下一代诊断测试赋予个体控制自己的健康。获得创新认可的FreeStyle Libre 3提供持续血糖监测，而Lingo持续血糖监测技术正准备扩展到美国市场。"
}